Review of the possible association between thyroid and breast carcinoma

• Published in: World journal of surgical oncology 2018-07, Vol.16 (1), p.130-130, Article 130
• Main Authors: Dong, Liangbo, Lu, Jun, Zhao, Bangbo, Wang, Weibin, Zhao, Yupei
• Format: Article
• Language: English
• Subjects: Breast cancer; Breast carcinoma; Breast Neoplasms - complications; Cancer; Etiology; Etiology (Medicine); Female; Females; Folic acid; Health risks; Hormones; Humans; Hypothalamus; Iodides; Iodine; Iodine 131; Iodine radioisotopes; Iodine Radioisotopes - therapeutic use; Metabolism; Obesity; Pituitary; Prognosis; Radiation therapy; Review; Risk analysis; Risk Factors; Sodium; Sodium iodide symporter; Studies; Systematic review; Thyroid; Thyroid cancer; Thyroid hormone; Thyroid hormone receptor; Thyroid Neoplasms - complications; Thyroid Neoplasms - etiology; Thyroid Neoplasms - therapy; Thyroid-stimulating hormone
• ISSN: 1477-7819; 1477-7819
• DOI: 10.1186/s12957-018-1436-0

Thyroid and breast cancer are two of the malignant diseases with highest incidence in females. Based on clinical experience, breast and thyroid cancer often occur metachronously or synchronously. Therefore, thyroid and breast cancer might share some common etiological factors. The relationship between these diseases has attracted substantial attention, and because these two glands are both regulated by the hypothalamic-pituitary axis, such a relationship is not surprising. A study of this relationship will be useful for obtaining a better understanding of the mechanism by which these two malignancies co-occur. This study reviewed the progress in research on the roles of iodine intake, folate metabolism, obesity, gonadal hormones, and thyroid hormone in thyroid and breast cancer. These studies evaluating the etiological roles of these factors in linking breast and thyroid cancer might also improve our understanding and identify new therapeutic approaches, such as sodium/iodide symporter-mediated radioiodine therapy and thyroid-stimulating hormone receptor antagonists, for breast cancer. In addition, some specific treatments for each cancer, such as radiotherapy for breast cancer or radioactive iodine therapy for thyroid cancer, might be risk factors for secondary malignances, including breast and thyroid cancer. Studies of the precise relationship between the co-occurrence of breast and thyroid cancer will certainly improve our understanding of the biological behaviors of these two malignancies and direct evidence-based clinical practice.